NanoViricides Inc. (NNVC)

[Raffis]

NV-COV-2-R encapsulation enhances Remdesivir-plasma-concentration through slower metabolism. This increases bio-availability, demonstrating that smaller dosages of Remdesivir can be administered with greater efficacy and safety and less residual drug toxicity.

https://www.benzinga.com/node/23025282

“The animal study showed that almost double the remdesivir remained intact in plasma when given as the encapsulated NV-CoV-2-R form, compared to the standard remdesivir formulation in Sulfobutylether-ß-cyclodextrin sodium salt (SBECD), during the first day of dosing.
Additionally, remdesivir accumulation was observed on repeated dosing of NV-CoV-2-R.
After the fifth dose and following the standard remdesivir dosing pattern, the circulating level of remdesivir in plasma was 75% greater in the NV-Cov-2-R group than in the remdesivir group.
The increased intact circulating level did not increase toxicity.
These data demonstrate that the pan-coronavirus nanopviricide drug candidate NV-CoV-2-R minimizes the loss of remdesivir to bodily metabolism.”